Table 2.
Astrocytoma survival association with kallikrein protein expression
| Univariable | Adjusteda | |||||
|---|---|---|---|---|---|---|
| HR | 95 % CI | P | HR | 95 % CI | P | |
| KLK1 | ||||||
| Intensity | 0.93 | 0.49–1.78 | 0.83 | 1.10 | 0.54–2.23 | 0.80 |
| Percent | 1.21 | 0.81–1.80 | 0.36 | 1.41 | 0.92–2.15 | 0.11 |
| IR | 1.08 | 0.96–1.21 | 0.21 | 1.13 | 0.99–1.29 | 0.06 |
| KLK6 | ||||||
| Intensity | 0.89 | 0.42–1.90 | 0.77 | 0.73 | 0.32–1.68 | 0.46 |
| Percent | 1.63 | 1.06–2.50 | 0.03* | 1.35 | 0.87–2.10 | 0.18 |
| IR | 1.16 | 1.02–1.31 | 0.02* | 1.10 | 0.96–1.25 | 0.17 |
| KLK7 | ||||||
| Intensity | 1.25 | 0.61–2.56 | 0.54 | 0.95 | 0.45–2.03 | 0.90 |
| Percent | 1.96 | 0.91–4.22 | 0.09 | 1.91 | 0.87–4.19 | 0.11 |
| IR | 1.17 | 1.02–1.34 | 0.03* | 1.10 | 0.95–1.28 | 0.20 |
| KLK8 | ||||||
| Intensity | 0.87 | 0.46–1.66 | 0.68 | 0.84 | 0.40–1.78 | 0.65 |
| Percent | 0.91 | 0.66–1.25 | 0.54 | 0.96 | 0.68–1.36 | 0.81 |
| IR | 0.98 | 0.83–1.16 | 0.81 | 0.95 | 0.77–1.17 | 0.61 |
| KLK9 | ||||||
| Intensity | 0.65 | 0.38–1.13 | 0.13 | 0.64 | 0.36–1.14 | 0.13 |
| Percent | 2.25 | 1.21–4.22 | 0.01* | 1.68 | 0.86–3.30 | 0.13 |
| IR | 1.05 | 0.90–1.22 | 0.52 | 0.99 | 0.85–1.16 | 0.90 |
| KLK10 | ||||||
| Intensity | 1.14 | 0.59–2.20 | 0.70 | 0.99 | 0.46–2.12 | 0.97 |
| Percent | 0.99 | 0.66–1.48 | 0.94 | 1.10 | 0.72–1.69 | 0.67 |
| IR | 1.12 | 0.92–1.37 | 0.27 | 1.03 | 0.82–1.28 | 0.80 |
Cox proportional hazards regression analysis assessing the association of kallikrein protein expression in 60 grade IV astrocytoma specimens. *P ≤ 0.03, Cox proportional hazards regression analysis
aAdjusted for age, gender and performance score